First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis.

ABSTRACT:

Background

Patients with HER2-negative locally advanced or unresectable metastatic gastric cancer and gastroesophageal junction (G/GEJ) adenocarcinoma have limited first-line treatment options and a poor prognosis. The GLOW clinical trial showed that zolbetuximab plus capecitabine plus oxaliplatin (CAPOX) significantly prolonged these patients' overall survival (OS) and progression-free survival (PFS).

Objectives

This study evaluated the cost-effectiveness of zolbetuximab plus CAPOX as a first-line treatment for HER2-negative locally advanced or unresectable metastatic G/GEJ adenocarcinoma in the United States and China.

Design

The cost-effective analysis.

Methods

Based on the GLOW clinical trial data (NCT03653507), we constructed a 10-year Markov model to asse

SUBMITTER: Lei J 

PROVIDER: S-EPMC11583495 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature